ISSN print edition: 0366-6352 ISSN electronic edition: 1336-9075 Registr. No.: MK SR 9/7 Published monthly

3′-O-(3-Chloropivaloyl)quercetin, α-glucosidase inhibitor with multi-targeted therapeutic potential in relation to diabetic complications

Marta Soltesova-Prnova, Ivana Milackova, and Milan Stefek

Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dúbravská cesta 9, 84104 Bratislava, Slovakia

E-mail: milan.stefek@savba.sk

Abstract: The novel derivative of quercetin 3′-O-(3-chloropivaloyl)quercetin (CPQ) inhibited α-glucosidase in a non-competitive manner with an efficacy exceeding that of the parent quercetin. In addition, it inhibited aldose reductase isolated from rat lenses with an IC₅₀ in the low micromolar range and attenuated sorbitol accumulation in isolated rat eye lenses with an activity comparable with that of quercetin. Moreover, it scavenged stable free-radicals of DPPH more efficiently than did quercetin. By inhibiting α-glucosidase and affecting both the polyol pathway and oxidative stress, CPQ represents a promising agent for the multi-targeted pharmacology of diabetic complications.

Keywords: 3′-O-(3-chloropivaloyl)quercetin – α-glucosidase inhibitor – aldose reductase inhibitor – antioxidant – diabetic complications

Full paper is available at www.springerlink.com.

DOI: 10.1515/chempap-2016-0078

Chemical Papers 70 (11) 1439–1444 (2016)